Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
RYGB Mortality Benefit Higher in These Patients
Diabetes Care; ePub 2017 Jul 31; Lent, et al
The mortality benefits of Roux-en-Y gastric bypass (RYGB) appear to occur mostly in patients who have diabetes at the time of surgery, according to a study involving nearly 5,700 individuals.
Participants included people who had RYGB (n=3,242) and matched controls who didn’t (n=2,428). Investigators looked at mortality differences in patients in each group with and without diabetes. Among the results:
- All-cause mortality odds were 56% lower in patients with diabetes who underwent RYGB, compared with their counterparts who did not have surgery.
- Mortality was not significantly different in patients without diabetes in each group.
- Deaths rates from cardiovascular diseases, respiratory conditions, and diabetes were higher in with diabetes than they were in patients with diabetes who had surgery.
- Patients without diabetes who underwent RYGB were less likely to die of cancer and respiratory diseases than their counterparts in the control group.
Citation:
Lent M, Benotti P, Mirshahi T, et al. All-cause and specific-cause mortality risk after Roux-en-Y gastric bypass in patients with and without diabetes. [Published online ahead of print July 31, 2017]. Diabetes Care. doi:10.2337/dc17-0519.